ALDX — Aldeyra Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Lear Corp, Stratasys, American Express
U.S. STOCKS ON THE MOVE-Manchester United, Enovix, Meta
Aldeyra Therapeutics up as drug reduces cough in mid-stage trial
Brief: Aldeyra Therapeutics Results of Phase 2 Clinical Trial Of ADX‑629 In Patients With Chronic Cough
Brief: Aldeyra Therapeutics To Join The Russell 2000 And Russell 3000 Indexes
U.S. STOCKS ON THE MOVE-PureCycle, Amazon.com, Dollar Tree
U.S. STOCKS ON THE MOVE-PureCycle, Walt Disney, Chipotle Mexican Grill
Aldeyra Therapeutics slumps as FDA declines to approve eye cancer drug
U.S. STOCKS ON THE MOVE-Adobe, Nikola, copper miners
U.S. STOCKS ON THE MOVE-Premier, Canadian Solar, Jabil
U.S. STOCKS ON THE MOVE-Premier, Canadian Solar, Jabil
U.S. STOCKS ON THE MOVE-Kohl's, JinkoSolar, Kroger
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Aldeyra Therapeutics eye treatment meets late-stage study main goal (updated)
Aldeyra Therapeutics rises as eye treatment meets late-stage study goals
Brief: Aldeyra Therapeutics Announces Achievement Of Statistical Significance For Primary Endpoint In Phase 3 Invigorate‑2 Trial Of Reproxalap In Allergic Conjunctivitis
Aldeyra Therapeutics eye treatment meets late-stage study main goal
Aldeyra Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results And Recent Corporate Highlights